Detalhe da pesquisa
1.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37248424
2.
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Target Oncol
; 18(4): 559-570, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369815
3.
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
Clin Genitourin Cancer
; 21(5): e309-e319.e1, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37062658
4.
Statins and renal cell carcinoma: Antitumor activity and influence on cancer risk and survival.
Crit Rev Oncol Hematol
; 176: 103731, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35718065
5.
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Clin Genitourin Cancer
; 20(3): 285-295, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35305916
6.
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies.
Target Oncol
; 17(5): 571-581, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35947324